<p>佛罗里达州迈尔斯堡 --（商业资讯）--NeoGenomics, Inc.（纳斯达克代码：NEO），一家领先的肿瘤诊断解决方案提供商，今天宣布任命诊断和实验室服务行业资深人士 John P. “Jack” Kenny 为其董事会成员。Kenny 先生将填补由 Alison Hannah 博士 vacated 的席位，后者在董事会服务超过十年后将卸任。</p>
<p>Kenny 先生为 NeoGenomics 董事会带来了超过三十年的多元化高管、商业和运营经验，以及在诊断和实验室服务业务中的成功记录。他最近担任 Meridian Bioscience 的总裁、首席执行官和董事会成员，该公司是一家全面整合的生命科学公司，开发、制造和分销广泛的创新诊断产品和免疫测定及分子检测公司的关键原材料。Meridian 曾在纳斯达克交易所以 “VIVO” 代码交易，于 2023 年 1 月被私有化。</p>
<p>“我们非常高兴欢迎 Jack 加入 NeoGenomics 董事会，” NeoGenomics 董事会主席 Lynn Tetrault 表示。“他在建立成功文化和领导高绩效商业团队方面的丰富经验，将在我们追求下一代癌症检测的重要新兴机会时为我们提供很大帮助，特别是在 NGS 和 MRD 领域。我期待他的见解和指导。”</p>
<p>“我还想感谢 Hannah 博士在过去十年中的战略指导，以及她对 NeoGenomics 使命的坚定承诺，即通过改善患者护理来拯救生命。她的贡献是无价的，” Tetrault 女士总结道。</p>
<p>在 2017 年加入 Meridian Bioscience 之前，Kenny 先生曾担任西门子医疗北美区高级副总裁和总经理，之前则担任贝克顿·迪金森美国地区副总裁和总经理。在他的职业生涯早期，他曾在 Leica Biosystems、Quest Diagnostics、西门子医疗解决方案和雅培实验室担任销售领导职务。Kenny 先生还在 OraSure Technologies, Inc.、DCN Diagnostics 和 Quantum-Si, Inc.的董事会任职。他获得了 Kettering University（前身为 GMI 工程与管理学院）管理系统学士学位，专注于市场营销。</p>
<p>“我认识 NeoGenomics 已经很多年了，我相信他们在血液学癌症检测中的领导地位使他们能够将创新带到最需要的地方——社区环境——改善患者结果，同时为股东创造持续价值，” Kenny 先生表示。“我期待与我的董事会同事和充满激情的 NeoGenomics 领导团队一起工作，帮助公司度过下一个增长阶段。”</p>
<p><strong>关于 NeoGenomics</strong></p>
<p>NeoGenomics, Inc.是一家顶尖的癌症诊断公司，专注于癌症遗传检测和信息服务。我们提供涵盖癌症全周期的最全面的肿瘤学检测菜单之一，为肿瘤科医生、病理学家、医院系统、学术中心和制药公司提供创新的诊断和预测检测，帮助他们诊断和治疗癌症。NeoGenomics 总部位于佛罗里达州迈尔斯堡，在美国运营一网络的 CAP 认证和 CLIA 认证实验室，提供全方位的样本处理和分析服务，并在英国剑桥设有一家 CAP 认证的全方位样本处理实验室。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含前瞻性声明。这些前瞻性声明通常可以通过使用 “预期”、“期望”、“计划”、“可以”、“可能”、“将”、“相信”、“估计”、“预测”、“目标”、“项目”、“指导”、“潜在” 等词语来识别，尽管并非所有前瞻性声明都包含这些词。每一项前瞻性声明都受到多种风险和不确定性的影响，这些风险和不确定性可能导致实际结果与这些声明所表达或暗示的结果有实质性差异。适用的风险和不确定性包括但不限于在公司年度报告 10-K 表格、季度报告 10-Q 表格和公司向证券交易委员会提交的其他文件中列出的 “风险因素”。</p>
<p>我们提醒投资者不要对本新闻稿中的前瞻性声明过于依赖。您被鼓励阅读我们向 SEC 提交的文件，这些文件可在 www.sec.gov 上找到，并在我们网站的 “投资者” 部分（ir.neogenomics.com）中讨论这些及其他风险和不确定性。本新闻稿中的前瞻性声明仅在本文件日期（除非另有说明）时有效，我们不承担更新或修订这些声明的义务。我们的业务面临重大风险和不确定性，包括上述提到的风险。投资者、潜在投资者和其他人应仔细考虑这些风险和不确定性。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMzA1NjU4NTFyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMzA1NjU4NTFyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251230565851/en/</p>
<p><strong>投资者联系</strong></p>
<p>Kendra Webster</p>
<p>InvestorRelations@neogenomics.com</p>
<p><strong>媒体联系</strong></p>
<p>Andrea Sampson</p>
<p>asampson@sampsonprgroup.com</p>
<p>来源：NeoGenomics, Inc.</p>

<p>NeoGenomics, Inc. 已任命 John P. "Jack" Kenny 为董事会成员，填补 Alison Hannah, MD 离开的席位。Kenny 在诊断和实验室服务行业拥有超过 30 年的经验，曾担任 Meridian Bioscience 的总裁兼首席执行官。董事会主席 Lynn Tetrault 对 Kenny 在癌症检测方面的专业知识以及他对公司增长的潜在贡献表示兴奋。NeoGenomics 专注于肿瘤学诊断解决方案，并在美国和英国运营获得认证的实验室</p>

<p>FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran John P. “Jack” Kenny to its Board of Directors. Mr. Kenny is filling the seat vacated by Alison Hannah, MD, who is rotating off the Board after more than ten years of dedicated service.</p>
<div class="lb-trans"><p>佛罗里达州迈尔斯堡 --（商业资讯）--NeoGenomics, Inc.（纳斯达克代码：NEO），一家领先的肿瘤诊断解决方案提供商，今天宣布任命诊断和实验室服务行业资深人士 John P. “Jack” Kenny 为其董事会成员。Kenny 先生将填补由 Alison Hannah 博士 vacated 的席位，后者在董事会服务超过十年后将卸任。</p>
</div><p>Mr. Kenny brings to the NeoGenomics Board over three decades of diverse executive, commercial, and operational experience and a track record of success in the diagnostics and lab services businesses. He most recently served as President, Chief Executive Officer and Board Director of Meridian Bioscience, a fully integrated life science company that develops, manufactures and distributes a broad range of innovative diagnostic products and critical raw materials for immunoassay and molecular testing companies. Meridian, which formerly traded on the NASDAQ exchange under the ticker “VIVO,” was taken private in January 2023.</p>
<div class="lb-trans"><p>Kenny 先生为 NeoGenomics 董事会带来了超过三十年的多元化高管、商业和运营经验，以及在诊断和实验室服务业务中的成功记录。他最近担任 Meridian Bioscience 的总裁、首席执行官和董事会成员，该公司是一家全面整合的生命科学公司，开发、制造和分销广泛的创新诊断产品和免疫测定及分子检测公司的关键原材料。Meridian 曾在纳斯达克交易所以 “VIVO” 代码交易，于 2023 年 1 月被私有化。</p>
</div><p>“We are very excited to welcome Jack to the NeoGenomics Board,” said Lynn Tetrault, Chair of the Board of NeoGenomics. “His vast experience building winning cultures and leading high performance commercial teams will serve us well as we pursue significant emerging opportunities in the next generation of cancer testing, notably NGS and MRD. I look forward to his insights and guidance.”</p>
<div class="lb-trans"><p>“我们非常高兴欢迎 Jack 加入 NeoGenomics 董事会，” NeoGenomics 董事会主席 Lynn Tetrault 表示。“他在建立成功文化和领导高绩效商业团队方面的丰富经验，将在我们追求下一代癌症检测的重要新兴机会时为我们提供很大帮助，特别是在 NGS 和 MRD 领域。我期待他的见解和指导。”</p>
</div><p>“I would also like to thank Dr. Hannah for her strategic guidance over the past decade and her unwavering commitment to NeoGenomics’ mission to save lives by improving patient care. Her contributions have been invaluable,” Ms. Tetrault concluded.</p>
<div class="lb-trans"><p>“我还想感谢 Hannah 博士在过去十年中的战略指导，以及她对 NeoGenomics 使命的坚定承诺，即通过改善患者护理来拯救生命。她的贡献是无价的，” Tetrault 女士总结道。</p>
</div><p>Prior to joining Meridian Bioscience in 2017, Mr. Kenny served as SVP and General Manager of North America at Siemens Healthcare and, before that, as VP and General Manager of the U.S. region at Becton Dickinson. Earlier in his career, he held sales leadership positions at Leica Biosystems, Quest Diagnostics, Siemens Medical Solutions, and Abbott Laboratories. Mr. Kenny also serves on the Boards of OraSure Technologies, Inc., DCN Diagnostics, and Quantum-Si, Inc. He received a BS in management systems with a focus in marketing from Kettering University (formerly the GMI Engineering and Management Institute).</p>
<div class="lb-trans"><p>在 2017 年加入 Meridian Bioscience 之前，Kenny 先生曾担任西门子医疗北美区高级副总裁和总经理，之前则担任贝克顿·迪金森美国地区副总裁和总经理。在他的职业生涯早期，他曾在 Leica Biosystems、Quest Diagnostics、西门子医疗解决方案和雅培实验室担任销售领导职务。Kenny 先生还在 OraSure Technologies, Inc.、DCN Diagnostics 和 Quantum-Si, Inc.的董事会任职。他获得了 Kettering University（前身为 GMI 工程与管理学院）管理系统学士学位，专注于市场营销。</p>
</div><p>“I have known NeoGenomics for many years, and I believe their leadership position in hematology cancer testing positions them well to deliver innovation to where it’s needed most – the community setting – improving patient outcomes while creating sustained value for shareholders,” said Mr. Kenny. “I look forward to working alongside my fellow Board members and the passionate NeoGenomics leadership team to help guide the Company through its next phase of growth.”</p>
<div class="lb-trans"><p>“我认识 NeoGenomics 已经很多年了，我相信他们在血液学癌症检测中的领导地位使他们能够将创新带到最需要的地方——社区环境——改善患者结果，同时为股东创造持续价值，” Kenny 先生表示。“我期待与我的董事会同事和充满激情的 NeoGenomics 领导团队一起工作，帮助公司度过下一个增长阶段。”</p>
</div><p><strong>About NeoGenomics</strong></p>
<div class="lb-trans"><p><strong>关于 NeoGenomics</strong></p>
</div><p>NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.</p>
<div class="lb-trans"><p>NeoGenomics, Inc.是一家顶尖的癌症诊断公司，专注于癌症遗传检测和信息服务。我们提供涵盖癌症全周期的最全面的肿瘤学检测菜单之一，为肿瘤科医生、病理学家、医院系统、学术中心和制药公司提供创新的诊断和预测检测，帮助他们诊断和治疗癌症。NeoGenomics 总部位于佛罗里达州迈尔斯堡，在美国运营一网络的 CAP 认证和 CLIA 认证实验室，提供全方位的样本处理和分析服务，并在英国剑桥设有一家 CAP 认证的全方位样本处理实验室。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential” and other words of similar meaning, although not all forward-looking statements include these words. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the risks identified under the heading &#34;Risk Factors&#34; contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明。这些前瞻性声明通常可以通过使用 “预期”、“期望”、“计划”、“可以”、“可能”、“将”、“相信”、“估计”、“预测”、“目标”、“项目”、“指导”、“潜在” 等词语来识别，尽管并非所有前瞻性声明都包含这些词。每一项前瞻性声明都受到多种风险和不确定性的影响，这些风险和不确定性可能导致实际结果与这些声明所表达或暗示的结果有实质性差异。适用的风险和不确定性包括但不限于在公司年度报告 10-K 表格、季度报告 10-Q 表格和公司向证券交易委员会提交的其他文件中列出的 “风险因素”。</p>
</div><p>We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and in the “Investors” section of our website at ir.neogenomics.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.</p>
<div class="lb-trans"><p>我们提醒投资者不要对本新闻稿中的前瞻性声明过于依赖。您被鼓励阅读我们向 SEC 提交的文件，这些文件可在 www.sec.gov 上找到，并在我们网站的 “投资者” 部分（ir.neogenomics.com）中讨论这些及其他风险和不确定性。本新闻稿中的前瞻性声明仅在本文件日期（除非另有说明）时有效，我们不承担更新或修订这些声明的义务。我们的业务面临重大风险和不确定性，包括上述提到的风险。投资者、潜在投资者和其他人应仔细考虑这些风险和不确定性。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMzA1NjU4NTFyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251230565851r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251230565851/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251230565851/en/</p>
</div><p><strong>Investor Contact</strong></p>
<div class="lb-trans"><p><strong>投资者联系</strong></p>
</div><p>Kendra Webster</p>
<div class="lb-trans"><p>Kendra Webster</p>
</div><p>InvestorRelations@neogenomics.com</p>
<div class="lb-trans"><p>InvestorRelations@neogenomics.com</p>
</div><p><strong>Media Contact</strong></p>
<div class="lb-trans"><p><strong>媒体联系</strong></p>
</div><p>Andrea Sampson</p>
<div class="lb-trans"><p>Andrea Sampson</p>
</div><p>asampson@sampsonprgroup.com</p>
<div class="lb-trans"><p>asampson@sampsonprgroup.com</p>
</div><p>Source: NeoGenomics, Inc.</p>
<div class="lb-trans"><p>来源：NeoGenomics, Inc.</p>
</div>

NeoGenomics 任命诊断和实验室服务行业资深人士 John P. “Jack” Kenny 加入其董事会 | NEO 股票新闻